Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind study of Advair Diskus versus Flovent Diskus in asthma
2015-004892-61Phase 4
- Sponsor
- GSK
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of salmeterol + fluticasone, fluticasone propionate nasal spray, salmeterol and fluticasone propionate in asthma and persistent asthma (2 arms), sponsored by GSK. Primary endpoint: Change in FEV1 over 52 weeks.
02
Drugs
salmeterol + fluticasonefluticasone propionate nasal spraysalmeterolfluticasone propionate
03
Conditions
asthmapersistent asthma
Beyond the preview
Go deeper on 2015-004892-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004892-61.